Checkerboard Transformational
Checkerboard Transformational

Transformational Science

Qu Biologics is pioneering the development of SSIs, a first-in-class immunotherapy platform. SSIs emerged from Qu’s seminal discovery that the body’s natural immune response may be harnessed and directed to specific organs. SSIs overcome immune dysfunction that underlies cancer, chronic inflammatory diseases, metabolic disease, and aging.

Learn More

Mission Statement

Qu’s mission is to transform the treatment and prevention of cancer, chronic inflammatory diseases, and metabolic disease, by restoring the full breadth of normal immune function.

Learn More

Checkerboard Mission
Checkerboard Mission
Checkerboard Trials
Checkerboard Trials

Current Clinical Trial

Qu Biologics currently has a Phase 2 randomized double-blind placebo-controlled clinical trial in progress:

Our PERIOP-06 Study is designed to evaluate whether Qu’s QBECO SSI can prevent post-operative innate immune suppression and improve survival in people with late-stage colon cancer undergoing surgery for liver metastasis.

Learn More

Pipeline

Qu Biologics is advancing the promise of SSIs across multiple important diseases, including oncology, chronic inflammatory diseases, metabolic disease, and diseases of aging.

Learn More

Qu Biologics Pipeline
Checkerboard Pipeline

Latest News

Checkerboard Trials
10 Feb 2025
Clinical News, News, Uncategorized
Qu Biologics’ Immunomodulator Clears Senescence
More
Blog Post Placeholder Image4
06 Jan 2025
Clinical News, News, Technology News
Qu Biologics’ Immunomodulator Improves Fatty Liver Disease
More
Blog Post Placeholder Image2
16 Dec 2024
Clinical News, News, Technology News
Qu Biologics’ Site Specific Immunomodulator Enables CAR T-cell Cancer Efficacy in Solid Tumor
More
join us

Careers

Join a team of innovators who have a passion to make a difference. Our ambitious team
has achieved a number of major milestones, and we have many big goals ahead.

Learn More